2019 Russ Prize
ATHENS, OHIO (January 3, 2019) -- 91探花 and the announce today that the 2019 Fritz J. and Dolores H. Russ Prize will be given to Julio Palmaz, Leonard Pinchuk, John Simpson, Richard Schatz and Paul Yock for innovations leading to the widespread adoption of percutaneous coronary intervention (PCI), previously known as angioplasty with stent or coronary angioplasty. The $500,000 biennial prize, which recognizes a bioengineering achievement that significantly improves the human condition, cites PCI for 鈥渟eminal contributions to coronary angioplasty, enabling minimally invasive treatment of advanced coronary artery disease.鈥
鈥淭he Russ Prize recipients personify engineering creations that advance health and health care every day,鈥 said NAE President C. D. Mote, Jr. 鈥淭he PCI makes a remarkable contribution to patient well-being, helping millions afflicted with advanced coronary artery disease and significant angina.鈥
91探花 alumnus and esteemed engineer Fritz Russ, BSEE 鈥42, HON 鈥75, and his wife, Dolores Russ, established the biennial prize in 1999 with a multimillion dollar gift to 91探花. They modeled after the Nobel Prize, with the goal of recognizing bioengineering achievements worldwide that are in widespread use.
鈥淭his innovation -- truly, sets of innovations -- enables the treatment of coronary artery disease without the complexities, cost and risk of open heart surgery. Most of us have a friend or relative who has benefited greatly from angioplasty treatment,鈥 said Russ College Dean Dennis Irwin. 鈥淭hese contributions have truly improved the human condition. Rewarding such innovations was the Russes鈥 intent.鈥
Percutaneous coronary intervention, also referred to as percutaneous transluminal coronary angioplasty (PTCA), is a minimally invasive procedure that uses a catheter to place a small structure called a stent to open up blood vessels in the heart that have been narrowed by plaque buildup. PCI improves blood flow, thus decreasing heart-related chest pain, making patients feel better and increasing their ability to be active. Ten of millions of patients have benefited from PCI worldwide, and this procedure has replaced or significantly delayed the need for open heart coronary bypass surgery.
Julio C. Palmaz, inventor of the first FDA-approved balloon-expandable vascular stent (1990), is Ashbel Smith Professor at the University of Texas Health Science Center in San Antonio and scientific adviser of Vactronix Scientific. The Palmaz stent is on display at the Smithsonian鈥檚 National Museum of American History in Washington, D.C. In 1994 he and Richard Schatz created a modified coronary stent 鈥 two Palmaz stents joined by a single connector 鈥 approved by the FDA as the first stent indicated for the treatment of failure of coronary balloon angioplasty. The Palmaz-Schatz stent became the gold standard for every subsequent stent submitted for FDA approval.
Leonard Pinchuk is an inventor and entrepreneur in biomedical engineering, with 128 U.S. patents and 90 publications. He has co-founded 10 companies where his major accomplishments include invention of the Nylon 12 angioplasty balloon, helical wire stent, modular stent-graft, a drug-eluting stent (TAXUS庐), several biomaterials (Bionate and poly(styrene-block-isobutylene-block-styrene) [SIBS]), a novel glaucoma tube (InnFocus MicroShunt庐), and the next generation intraocular lens. He is a Distinguished Research Professor of Biomedical Engineering at the University of Miami.
John Simpson has helped revolutionize the field of cardiology through innovations that fundamentally altered how physicians treat cardiovascular disease. In 1981 he created a new catheter system for coronary angioplasty with an independently steerable guidewire in the central lumen of the balloon catheter, patented as the over-the-wire balloon angioplasty catheter. He now focuses his efforts on the treatment of vascular disease through the development of new technologies combined with a new approach to optical imaging.
Richard Schatz is research director of cardiovascular interventions at the Scripps Heart, Lung, and Vascular Center and director of gene and stem cell therapy. He is a recognized international expert in interventional cardiology and has published and lectured extensively. His seminal work in coronary stents spurred a revolution in the treatment of coronary artery disease鈥攐ver 2 million of them are placed annually worldwide, with an immeasurable impact on relieving mortality and morbidity, improving patients鈥 lives, and reducing health care costs.
Paul Yock is the Martha Meier Weiland Professor of Medicine and founding co-chair of Stanford鈥檚 Department of Bioengineering, with courtesy appointments in the Graduate School of Business and the Department of Mechanical Engineering. He is also founder and director of the Stanford Byers Center for Biodesign. He has authored over 300 peer-reviewed publications, chapters, and editorials and two textbooks, and holds over 50 U.S. patents. Yock is internationally known for his work in inventing, developing, and testing new devices, including the Rapid Exchange鈩 stenting and balloon angioplasty system, which is now the primary system in use worldwide. He also invented the fundamental approach to intravascular ultrasound imaging and founded Cardiovascular Imaging Systems (CVIS), later acquired by Boston Scientific.
鈥91探花 is honored to join the National Academy of Engineering in recognizing these accomplished individuals, who have contributed to a bioengineering advancement that has enabled better health for heart patients across the world,鈥 said 91探花 President M. Duane Nellis. 鈥淭heir multi-disciplinary collaboration that lead to the development of PCI, a technology that has revolutionized coronary health, truly embraces the vision that Fritz and Dolores Russ had when creating the Russ Prize.鈥
Palmaz, Pinchuk, Schatz, Simpson, and Yock are the 10th recipients of the Russ Prize. They will receive the award at a National Academy of Engineering gala ceremony in Washington, D.C., on Feb. 20.
Colleen Carow and Marissa McDaid contributed to this story.